Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Chronic Lymphocytic Leukemia
Interventions: Pembrolizumab, Ibrutinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: temsirolimus, conventional surgery, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: brachytherapy; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Caregiver, Glioma
Interventions: Best Practice, Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Yoga; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 78
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more

Conditions: Uterine Fibroids
Interventions: MR-HIFU treatment, Sham treatment; Device
Lead sponsor: Philips Healthcare; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Chicago, Illinois • Ann Arbor, Michigan • The Bronx, New York + 4 more

Conditions: Angina, Heart Disease
Interventions: Ranolazine; Drug
Lead sponsor: Westside Medical Associates of Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions: curcumin, Biomarker analysis, Assessment of Dietary Intake, Daily Log; Dietary Supplement · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Glioblastoma
Interventions: Paxalisib, Metformin, Ketogenic Diet; Drug · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Interventions: Azacitidine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infection
Interventions: exercise training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Decatur, Georgia • Baltimore, Maryland • Salem, Virginia

Conditions: Higher-risk Myelodysplastic Syndrome
Interventions: Lisaftoclax (APG-2575), Azacitidine Injection, Placebo; Drug · Other
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more

Conditions: Type 2 Diabetes
Interventions: High Glycemic Diet, Control diet; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Brain Tumors, Solid Tumor
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 138 participants
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Anxiety
Interventions: Facial Microexpression Training; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
Interventions: Temozolomide, hypofractionated radiation therapy, bevacizumab, questionnaire administration; Drug · Radiation · Biological + 1 more
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Lake Forest, Illinois • Naperville, Illinois + 1 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spinal Cord Stimulation, High-frequency Stimulation, High-density Stimulation
Interventions: High-frequency stimulation, Sham Stimulation; Device
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Substance Use (Drugs, Alcohol), Health Risk Behaviors, Youth, Adolescent Behavior
Interventions: iDECIDE; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Emergency Service, Hospital
Interventions: Information about scheduling a follow-up appointment; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6,814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Prostate Cancer
Interventions: Pasritamig; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bone Loss in Jaw, Dental Diseases
Interventions: Ultrasound Scan; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostatic Hyperplasia
Interventions: Polyphenon E, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 30 Years to 80 Years · Male only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 10
States / cities: Gainesville, Florida • Jacksonville, Florida • Lakeland, Florida + 5 more

Conditions: Chronic Kidney Diseases, High Cholesterol
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Search by objective public record fields.

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

Multi-catheter High Dose Rate (HDR) Breast Brachytherapy

Couples-Based Yoga Program in Improving Quality of Life in Patients With High-Grade Glioma Undergoing Radiation Therapy and Their Partners

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Functional Interval Training for Veterans Exercising Through Telehealth.

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

"Effect of High Fat and High Glycemic Diets

Understanding Communication in Healthcare to Achieve Trust (U-CHAT)

Assessing Visual Processing in High Anxiety

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

High Dose Influenza in Immunosuppressed Subjects

Direct Comparison of Spinal Cord Stimulator Parameter Settings

Pilot of a Drug Education Curriculum for Middle and High School Students

Nudging High-acuity Emergency Department Patients to Schedule a Follow-up Visit

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

Point of Care, High Resolution and 3-Dimensional Ultrasonography

Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

Evolocumab In Advanced Chronic Kidney Disease Trial